Updates are available Correction dated 2024-01-20
Click to view Correction: https://doi.org/10.1007/s13555-023-01076-x
-
Authors
Rand, Kim http://orcid.org/0000-0001-7692-4099
Ramos-Goñi, Juan Manuel http://orcid.org/0000-0002-9568-5190
Akmaz, Bülent
Solé-Feu, Laia
Armario-Hita, José-Carlos http://orcid.org/0000-0001-6620-4725
-
Funding
Funding for this research was provided by:
Almirall
- License Information
-
More Information
Article History
Received: 6 September 2023
Accepted: 10 October 2023
First Online: 28 October 2023
Change Date: 20 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13555-023-01076-x
Declarations
:
: Kim Rand and Juan Manuel Ramos-Goñi are employees of the consultancy Maths in Health B.V., and in this capacity have received research funding from several companies in the pharmaceutical industry, including Almirall S.A. Bülent Akmaz and Laia Solé-Feu are employees of Almirall S.A. José-Carlos Armario-Hita reports grants or contracts from AbbVie, Sanofi, Novartis, Leo Pharma,Janssen, Almirall, Lilly, UCB, Gebro; has received consulting fees and payment or honoraria from AbbVie, Sanofi,Novartis, Leo Pharma, Janssen, Lilly, and UCB.
: This study involved secondary analysis of a limited subset of data from the ADvocate 1 and 2 clinical trials, which were undertaken in accordance with the ethical principles of the Declaration of Helsinki, including informed consent from study participants. The article does not contain any studies with human participants or animals performed by any of the authors. Permission to analyze and disclose results from the ADvocate trials was provided by Eli Lilly and Almirall.
